{
bluebird bio, Inc.

Companies

}
Symbol BLUE
Name bluebird bio, Inc.
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country United States
State MA
City Cambridge
Zipcode 2142
Website http://www.bluebirdbio.com
Track all markets on TradingView
CRISPR Therapeutics gains momentum with new Medicaid plan for gene therapy access
CRISPR Therapeutics has faced a challenging market, with shares down 23% year-to-date despite recent regulatory approvals for its gene-editing medicine, Casgevy, which treats sickle cell disease and beta-thalassemia. The Biden administration's new Medicaid initiative aims to improve access to Casgevy, potentially expanding its market significantly. With a projected peak annual sales exceeding $2.2 billion, the company is well-positioned for future growth, although it currently reports minimal revenue.
The Motley Fool
United States Dollar Vertex Pharmaceuticals Inc bluebird bio, Inc. CRISPR Therapeutics AG SAU USA BHR GBR Show more
Healthcare, Market Report
18:25 22.12.2024
editas medicine lays off staff and shifts focus to in vivo gene editing
Editas Medicine will lay off 180 employees, about two-thirds of its workforce, as it shifts focus to “in vivo” gene editing after failing to find a partner for its sickle cell therapy. The company is ending development of its lead CRISPR medicine and will share more preclinical data in early 2025.
BioPharma Dive
United States Dollar bluebird bio, Inc. CRISPR Therapeutics AG Editas Medicine, Inc. Baisong Mei Gilmore O’Neill Show more
Technology & Innovation, News Article
01:00 12.12.2024
AstraZeneca and Daiichi Sankyo Advance Cancer Drug Amid Industry Developments
AstraZeneca and Daiichi Sankyo announced new study results for their cancer drug datopotamab deruxtecan, showing a median survival of 15.6 months in patients with EGFR-mutated non-small cell lung cancer. Agenus plans to cut annual spending by 60% to focus on a late-stage cancer immunotherapy, while Amgen is investing $1 billion to expand its manufacturing in North Carolina. The U.S. Patent and Trademark Office has withdrawn a proposed rule aimed at reducing patent thickets, and Bluebird bio is executing a reverse stock split to comply with Nasdaq rules. Merus received FDA accelerated approval for zenocutuzumab, its first approved product.
BioPharma Dive
bluebird bio, Inc. AstraZeneca PLC Daiichi Sankyo Co Ltd Amgen Inc. Merus N.V. Delilah Alvarado Ned Pagliarulo Jonathan Gardner Ben Fidler Show more
Healthcare, News Article
01:00 06.12.2024
CMS Partners with Drug Makers to Enhance Sickle Cell Therapy Access Model
The Centers for Medicare & Medicaid Services has negotiated agreements with Vertex Pharmaceuticals and bluebird bio to include their sickle cell disease treatments, Casgevy and Lyfgenia, in a new Cell and Gene Therapy Access Model. This voluntary model allows states in the Medicaid Drug Rebate Program to apply for funding based on the drugs' effectiveness in improving patient outcomes. With over 100,000 individuals affected by sickle cell disease in the U.S., the initiative aims to enhance access to innovative therapies while providing budget predictability for state Medicaid agencies.
Fierce Healthcare
United States Dollar bluebird bio, Inc. Vertex Pharmaceuticals Inc USA Liz Fowler
Healthcare, Press Release
16:19 04.12.2024
halozyme bids for evotec bluebird bio records first revenue beiGene rebrands
Halozyme Therapeutics has made an unsolicited bid to acquire Evotec for 11 euros per share, totaling around 2 billion euros, aiming to enhance its strategic position in the drug industry. Bluebird bio has recorded its first revenue from its gene therapy Lyfgenia for sickle cell disease, while BeiGene has rebranded as BeOne Medicines to emphasize its oncology focus and distance itself from its Chinese roots. Adaptimmune plans to lay off a third of its workforce to save $300 million and focus on its cell therapy Tecelra, while Abeona Therapeutics awaits a decision from the FDA on its gene therapy pz-cel for a rare skin condition by April 2025.
BioPharma Dive
Euro Leerink Partners LLC Abeona Therapeutics Inc. Evotec SE Adaptimmune Halozyme Therapeutics, Inc. BeOne Medicines bluebird bio, Inc. USA Grant Curry Ned Pagliarulo Ben Fidler Jason Truman Show more
Healthcare, News Article
01:00 15.11.2024
new data highlights cancer risks in gene therapy for childhood brain disorder
New data reveal a cancer risk associated with Skysona, a gene therapy for cerebral adrenoleukodystrophy (CALD), with seven cases of blood malignancies reported among 67 treated boys. While the therapy shows promise, concerns about its safety persist, prompting careful consideration by physicians and families. Bluebird bio, the therapy's developer, emphasizes patient well-being and informed decision-making amid ongoing scrutiny.
BioPharma Dive
United States Dollar bluebird bio, Inc. The New England Journal of Medicine USA Cynthia Dunbar Christine Duncan
Healthcare, News Article
09:55 10.10.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Banking Regulations Central Bank Actions Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Cryptocurrency & Blockchain Regulations Mergers & Acquisitions Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Cryptocurrency Regulations Emerging Startups SEC & Financial Compliance Inflation Rates & CPI Data Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN IND CHN CAN SGP DNK AUT LIE KOR NGA FIN COL VGB
Companies:
Credit Suisse Real Estate Fund Siat Coinbase Global, Inc. BlackRock, Inc. Solana USD Ripples USD Ethereum USD Apple Inc. Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Gary Gensler Thomas Jordan Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.